RCM
CORT icon

Riverhead Capital Management’s Corcept Therapeutics CORT Stock Holding History

Riverhead Capital Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-15,100
Closed -$168K – 1509
2019
Q2 		$168K Buy
15,100
+1,000
+7% +$11.1K 0.01% 1203
2019
Q1 		$165K Hold
14,100
– – 0.01% 1199
2018
Q4 		$188K Buy
14,100
+1,100
+8% +$14.5K 0.01% 1098
2018
Q3 		$182K Buy
13,000
+3,600
+38% +$50.3K 0.01% 1238
2018
Q2 		$148K Hold
9,400
– – 0.01% 1220
2018
Q1 		$155K Buy
+9,400
New +$174K 0.01% 1187

Other funds holding CORT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Riverhead Capital Management's CORT Position: Q3 2019 in Review

Riverhead Capital Management sold out of Corcept Therapeutics (CORT) in Q3 2019, closing a stake of 15,100 shares — an estimated $168K sold.

Riverhead Capital Management first reported a position in CORT in Q1 2018 and held it in 6 quarters. The position peaked at $188K in Q4 2018. 193 funds tracked by Wall St. Rank hold CORT as of Q3 2019.

  • Riverhead Capital Management reported no remaining Corcept Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Riverhead Capital Management sold 15,100 Corcept Therapeutics shares in Q3 2019, an estimated $168K.
  • Riverhead Capital Management first reported a position in Corcept Therapeutics in Q1 2018 and held it in 6 quarters.
  • Riverhead Capital Management's Corcept Therapeutics position peaked at $188K in Q4 2018.
  • 193 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2019.

Based on Riverhead Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.